Martingale Asset Management L P Gritstone Bio, Inc. Transaction History

Martingale Asset Management L P

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$4.03 - $12.19 $64,480 - $195,040	-16,000 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$8.76 - $13.71 $140,160 - $219,360	16,000 New	16,000 $205,000
Q4 2020 Feb 10, 2021	SELL	$2.57 - $4.22 $37,265 - $61,190	-14,500 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$2.63 - $8.09 $339,309 - $1.04 Million	-129,015 Reduced 89.9%	14,500 $38,000
Q2 2020 Aug 10, 2020	BUY	$5.69 - $8.17 $816,600 - $1.17 Million	143,515 New	143,515 $952,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.